echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > The "forgotten valve" ushered in the next "beat"?|HCare

    The "forgotten valve" ushered in the next "beat"?|HCare

    • Last Update: 2021-09-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The heart beats about 2.


    The human heart is as big as our fist and looks like a peach


    Heart structure diagram

    Image source: Siyu Medical Equipment Observation Official Account

    There are four doors in the "two rooms and two rooms", namely the aortic valve, pulmonary valve, mitral valve and tricuspid valve, collectively referred to as heart valves, which are used to accurately control the direction and flow of blood circulation


    According to incomplete statistics, there are at least 30 million patients with valvular disease in the country, especially with the aging of the population, the incidence of valvular disease in people over 65 has exceeded 6.


    At present, there are three types of clinical treatments for heart valve diseases: drug therapy, surgery, and transcatheter heart valve interventional therapy


    Drug therapy can only relieve the symptoms but cannot be cured


    With the vigorous development of interventional cardiology in recent years, transcatheter heart valve disease interventional replacement or repair treatment techniques characterized by minimal trauma, less pain, and quick recovery (mainly include two approaches: transapical and transvascular Approach) has been widely used clinically


    Interventional treatment of structural heart disease may have become the fourth revolution in cardiac interventional treatment


    Aortic valve stenosis (AS) often begins with focal thickening and hardening of the aorta, and gradually progresses to obstructive aortic valve stenosis characterized by thickening and calcification of the aortic valve, causing abnormal ventricular function


    Compared with the aortic valve, the global mitral valve and tricuspid valve are still in their infancy


    Mitral regurgitation (MR) is a common valvular heart disease.


    Transcatheter mitral valve repair/replacement (TMVR) is widely used in the treatment of mitral valve disease, especially for those with thin, short, fragile or calcified mitral valve disease, which cannot be repaired and treated by surgery.


    Tricuspid regurgitation is a neglected serious right heart system disease.


    However, the current treatment methods for tricuspid regurgitation are relatively limited, and the effect of medical treatment alone is very poor, and surgical repair or replacement is also very risky and often has a poor prognosis


    Compared with the development of transcatheter aortic valve and transcatheter mitral valve, the development of transcatheter tricuspid valve (TTVR) is relatively lagging behind


    With the development of transcatheter interventions for the aortic and mitral valves around the world, transcatheter tricuspid valve interventions have also begun to break the ice.


    Heart valve is a highly sophisticated industry closely related to life.
    It looks extremely compact.
    The materials, mechanics, biology and other high-precision technologies involved are even more difficult than electronic equipment.
    It can be described as "small valves, high barriers".
    , The big market"
    .

    Reference materials:

    [1]Transcatheter Tricuspid Valve Interventions: Landscape, Challenges, and Future Directions.
    Asmarats L, Puri R, Latib A, et al.
    J Am Coll Cardiol.
    2018 Jun 26;71(25):2935-2956.
    doi: 10.
    1016/ j.
    jacc.
    2018.
    04.
    031.

    [2]Transcatheter therapies for tricuspid valve regurgitation.
    Zaccone G, Di Pasquale M, Fiorina C, et al.
    2020 Dec;21(12):964-974.
    doi: 10.
    2459/JCM.
    0000000000001062.

    [3] Li Qingchen.
    Legend outside the heart.
    Beijing: Tsinghua University Press.
    2012.

    [4]Transcatheter Interventions for Tricuspid Valve Disease: What to Do and Who to Do it On.
    Muntané-Carol G, Alperi A, Faroux L, et al.
    Can J Cardiol.
    2021 Jan 22.
    doi: 10.
    1016/j.
    cjca.
    2020.
    12.
    029.

    [5]First-in-Man Experience of Transcatheter Tricuspid Valve Replacement With LuX-Valve in High-Risk Tricuspid Regurgitation Patients.
    Lu FL, Ma Y, An Z, et al.
    JACC Cardiovasc Interv.
    2020 Jul 13;13(13) :1614-1616.
    doi: 10.
    1016/j.
    jcin.
    2020.
    03.
    026.

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.